投稿咨詢
Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.
Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.
Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.
《Cardiovascular Drugs And Therapy》是一本由SPRINGER出版商出版的專業醫學期刊，該刊創刊于1987年，刊期Bimonthly，該刊已被國際權威數據庫SCI、SCIE收錄。在中科院最新升級版分區表中，該刊分區信息為大類學科：醫學 3區，小類學科：心臟和心血管系統 3區；藥學 3區；在JCR（Journal Citation Reports）分區等級為Q2。該刊發文范圍涵蓋心臟和心血管系統等領域，旨在及時、準確、全面地報道國內外心臟和心血管系統工作者在該領域取得的最新研究成果、工作進展及學術動態、技術革新等，促進學術交流，鼓勵學術創新。2021年影響因子為3.947，平均審稿速度平均4.5月。
| 大類學科 | 分區 | 小類學科 | 分區 | Top期刊 | 綜述期刊 |
| 醫學 | 3區 | CARDIAC & CARDIOVASCULAR SYSTEMS 心臟和心血管系統 PHARMACOLOGY & PHARMACY 藥學 | 3區 3區 | 否 | 否 |
| JCR分區等級 | JCR所屬學科 | 分區 | 影響因子 |
| Q2 | PHARMACOLOGY & PHARMACY | Q2 | 3.947 |
| CARDIAC & CARDIOVASCULAR SYSTEMS | Q2 |
| 影響因子 | h-index | Gold OA文章占比 | 研究類文章占比 | OA開放訪問 | 平均審稿速度 |
| 3.947 | 63 | 23.82% | 67.53% | 未開放 | 平均4.5月 |
課題、SCI/EI/SSCI怎么寫？